Genentech, a member of the Roche Group, is the founder of the biotechnology industry and pioneer of the processes and technologies used to commercially manufacture complex biologic medicines.

Genentech’s Oceanside, CA campus is located 35 miles north of San Diego, with seven buildings spanning 60 acres and ~575,000 square feet dedicated to multi-product manufacturing with parallel commercial production and launch capabilities.

Now, building on more than four decades of biologics manufacturing innovation, the Oceanside site has broken ground on a new facility at the forefront of next-generation manufacturing and environmentally sustainable production for small-batch commercial biologics.

ABOUT THE NEW FACILITY

Opening in early 2025, Oceanside’s new small-batch biologics facility will utilize the most advanced manufacturing technologies and modern, modular equipment to significantly increase speed and agility during the production of commercial medicines for patients.

- Represents the first commercial biopharma manufacturing facility to incorporate the latest manufacturing technologies along with in-house process improvements for increased flexibility, speed and output under one roof
- Serves as a new model for fast, efficient production of therapeutics for smaller patient populations, including personalized and rare disease medicines
- Leverages advances in single-use technology, automation and digital manufacturing
- Significantly reduces the time required to pivot from producing one medicine to another
- Mirrors Genentech’s Clinical Supply Center in South San Francisco, enabling tech transfers between the two sites at unprecedented speed

SUSTAINABILITY

The new Oceanside facility maximizes agility, speed and efficiency while using fewer resources, making it more environmentally friendly than traditional manufacturing facilities.

- 25% less energy
- 28% less water
- 14% less carbon
- Zero plastic waste to landfill

GLOBAL MANUFACTURING NETWORK

Roche and Genentech produce medicines at 11 sites around the world. The new Oceanside facility will be the first of its kind in the Roche global manufacturing network dedicated to full scale commercial production, and is part of a ~$700 million investment in advanced manufacturing capabilities in California.

In addition to ongoing investments in manufacturing innovation, Genentech invested $15 billion globally in research and development in 2021 – more than any other health care company in the world.